## **Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents**
### Authors: Jos√© L. Jimenez (jose_luis.jimenez@novartis.com), Mourad Tighiouart (mourad.tighiouart@cshs.org) and Mauro Gasparini (mauro.gasparini@polito.it)

